Article

Technology in trials: Early results promising for presbyopia reversal

Orlando-Early results from a clinical trial for the reversal and treatment of presbyopia, using SurgiLight Inc.'s OptiVision technology, appear "promising," according to researchers at New York-Presbyterian Hospital Weill Cornell Medical Center.

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Related Content
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
January 19th 2025

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
January 17th 2025

Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Cost-effectiveness of AI pediatric eye screening
January 17th 2025

Cost-effectiveness of AI pediatric eye screening

Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
January 16th 2025

Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT

© 2025 MJH Life Sciences

All rights reserved.